181641-49-6

Basic information

• Product Name: 1-benzyl-4-phenylpiperidin-4-aMine
• Synonyms: 1-benzyl-4-phenylpiperidin-4-aMine
• CAS NO: 181641-49-6
• Molecular Formula: C₁₈H₂₂N₂
• Molecular Weight: 266.38068
• Mol File: 181641-49-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 388.025°C at 760 mmHg
• Flash Point: 173.475°C
• Appearance: /
• Density: 1.083g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.596
• CAS DataBase Reference: 1-benzyl-4-phenylpiperidin-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-phenylpiperidin-4-aMine(181641-49-6)
• EPA Substance Registry System: 1-benzyl-4-phenylpiperidin-4-aMine(181641-49-6)

Safety Data

• Hazardous Substances Data: 181641-49-6(Hazardous Substances Data)

Usage

Piperidine derivative

A derivative of piperidine This compound is based on the piperidine structure, which is a six-membered heterocyclic ring containing one nitrogen atom.

Benzyl and phenyl substituents

Attached to the piperidine ring The benzyl group (a phenyl group attached to a methylene group) and the phenyl group (a six-membered aromatic ring) are both substituents on the piperidine ring, contributing to the compound's structure and properties.

Dopamine receptor antagonist

Activity as a dopamine receptor antagonist 1-benzyl-4-phenylpiperidin-4-amine has been found to have activity as a dopamine receptor antagonist, meaning it can block or inhibit the action of dopamine, a neurotransmitter, at its receptors.

Potential pharmacological properties

Investigated for its potential pharmacological properties This compound has been researched for its possible therapeutic effects, including its use in the treatment of certain medical conditions.

Synthesis of other organic compounds

Applications in the synthesis of other organic compounds 1-benzyl-4-phenylpiperidin-4-amine may also be used as a building block or intermediate in the synthesis of other organic compounds.

Health and safety hazards

Potential for health and safety hazards Due to its chemical nature, 1-benzyl-4-phenylpiperidin-4-amine should be handled and used with caution to avoid potential health and safety risks.

InChI:InChI=1/C18H22N2/c19-18(17-9-5-2-6-10-17)11-13-20(14-12-18)15-16-7-3-1-4-8-16/h1-10H,11-15,19H2

Upstream product

• 172733-78-7 N-(1-benzyl-4-phenylpiperidin-4-yl)acetamide 
• 63843-83-4 1-benzyl-4-hydroxy-4-phenylpiperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 591-51-5 phenyllithium 
• 41661-47-6 piperidin-4-one 
• 100-39-0 benzyl bromide 

Downstream Products

• 181641-53-2 1-Benzyl-4-(formylamino)-4-phenylpiperidine 
• 172734-92-8 (S)-(N)-(1-(3-(1-benzoyl-3(3,4-dichlorophenyl)piperidin-3-yl)propyl)-4-phenylpiperidin-4-yl)-N-methylacetamide 
• 182621-56-3 4-methylamino-4-phenylpiperidine 
• 182621-57-4 {3-(3,4-Dichloro-phenyl)-3-[3-(4-methylamino-4-phenyl-piperidin-1-yl)-propyl]-piperidin-1-yl}-phenyl-methanone 
• 172734-03-1 1-Benzyl-4-(methylamino)-4-phenylpiperidine 
• 172734-92-8 osanetant 
• 939801-31-7 C₃₃H₄₀FN₃O₃ 
• 3543-30-4 1'-benzyl-4'-phenyl-decahydro-[1,4']bipyridinyl 
• 1333494-95-3 N-((S)-2-amino-3-((S)-1-((S)-1-((2S,3R)-4-(1-benzyl-4-phenylpiperidin-4-ylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-ylamino)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-3-oxopropyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamide 
• 1333494-96-4 N-((S)-2-amino-3-((S)-1-((S)-1-((2S,3R)-4-(1-benzyl-4-phenylpiperidin-4-ylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-ylamino)-3-cyclohexyl-1-oxopropan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-3-oxopropyl)-5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamide 

Relevant articles and documents

Structure-guided design and synthesis of P1′ position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors

Previously, we reported potent pentapeptidic BACE1 inhibitors with the hydroxymethylcarbonyl isostere as a substrate transition-state mimic. To improve the in vitro potency, we further reported pentapeptidic inhibitors with carboxylic acid bioisosteres at the P4 and P1′ positions. In the current study, we screened new P1′ position 1-phenylcycloalkylamine analogs to find non-acidic inhibitors that possess double-digit nanomolar range IC50 values. An extensive structure-activity relationship study was performed with various amine derivatives at the P1′ position. The most potent inhibitor of this pentapeptide series, KMI-1830, possessing 1-phenylcyclopentylamine at the P 1′ position had an IC50 value of 11.6 nM against BACE1 in vitro enzymatic assay.

(3R)-3-Amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides and 3-amino-N-(4-aryltetrahydropyran-4-yl)butanamides were synthesized and evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors. Derivatives incorporating the 6-substituted benzothiazole group showed highly potent DPP-IV inhibitory activity. Oral administration of (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide (12u) reduced blood glucose excursion in an oral glucose tolerance test.

A reliable and efficient synthesis of SR 142801

A convenient synthesis of the potent human NK-3 receptor antagonist SR 142801, (S)-(+)-N-{{3-[1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]prop-1 -yl}-4-phenylpiperidin-4-yl}-N-methylacetamide [(S)-(+)-(15)], is described. Improvements over the previously reported procedure are the preparation of the intermediate 5 via the novel imide 3 and subsequent reaction with the nucleophile 14, which reacts, regioselectively, at the endocyclic nitrogen.